Advertisement ERT names interim CEO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ERT names interim CEO

ERT, a provider of technology and services to the pharmaceutical, biotechnology and medical device industries, has named Joel Morganroth as the interim CEO of the company, after the retirement of the current CEO Michael McKelve.

Morganroth is currently working as ERT’s chairman and chief scientific officer and has served as the chairman of ERT’s board of directors since 1999 and as chief scientific officer since April 2006.

He previously served as the company’s CEO from 1993 to March 2001 and also has consulted for ERT since 1977.

Morganroth said they thank McKelvey for his years of service and wish him well in his future endeavors.

"I will continue to leverage my experience and knowledge of the organization and domain expertise to strengthen our position in clinical research associated with Cardiac Safety, Respiratory and electronic Patient Reported Outcomes (ePRO)," Morganroth said.